Ageing, health status and coverage rate effects on community prescription costs in Ireland.

作者: Martin Kenneally , Brenda Lynch

DOI: 10.1007/S10198-017-0913-7

关键词:

摘要: This paper aims to explore how GMS drug costs depend on age, gender, income, health status, community scheme coverage rates and whether they display significant differences across regions of Ireland. We also aim find out whether the high low income cohorts respond similarly changes in their status. The projects 2026 examines the separate cost population ageing growth over period. simulate estimated model show much giving free prescription drugs all persons aged ‘under 5’ would add costs, universal costs. construct a multivariate logistic regression progress methodology used earlier studies by explicitly modelling regional incomes status interact determining An age cohort region breakdown simulated both projected demographic trends public policy measures that have been adopted or are under consideration, investigated. age—but not gender—on income, rates, significantly lower for Donegal North West region. tend increase as improves, whereas decrease improves. A uniform 1% gain has little impact total prescribing Similarly, if Irish improved match East 2010 it only reduced around 32 € million 1.8 € billion bill. minor doubled from circa 3.6 € billion.

参考文章(20)
M Kenneally, Walshe, Community drug expenditure and recent cost containment measures. Irish Medical Journal. ,vol. 106, pp. 44- ,(2013)
L Tilson, M Barry, Reimbursement of new high cost drugs--funding the unfundable? Irish Medical Journal. ,vol. 103, pp. 133- ,(2010)
Colm McCarthy, Pat McLaughlin, William Slattery, Maurice O'Connell, Donal McNally, Mary Walsh, Report of the Special Group on Public Service Numbers and Expenditure Programmes Research Papers in Economics. ,(2009)
Giuseppe Carone, Christoph Schwierz, Ana XAVIER, Cost-Containment Policies in Public Pharmaceutical Spending in the EU Social Science Research Network. ,(2012) , 10.2139/SSRN.2161803
Anne E. Sales, Chuan-Fen Liu, Kevin L. Sloan, Jesse Malkin, Paul A. Fishman, Amy K. Rosen, Susan Loveland, W. Paul Nichol, Norman T. Suzuki, Edward Perrin, Nancy D. Sharp, Jeffrey Todd-Stenberg, Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Medical Care. ,vol. 41, pp. 753- 760 ,(2003) , 10.1097/01.MLR.0000069502.75914.DD
Amaia Calderón-Larrañaga, Chad Abrams, Beatriz Poblador-Plou, Jonathan P Weiner, Alexandra Prados-Torres, Applying diagnosis and pharmacy-based risk models to predict pharmacy use in Aragon, Spain: the impact of a local calibration. BMC Health Services Research. ,vol. 10, pp. 22- 22 ,(2010) , 10.1186/1472-6963-10-22
J.-Matthias Graf von der Schulenburg, Management of cost and utilization of pharmaceuticals in Germany Health Policy. ,vol. 41, pp. S45- S53 ,(1997) , 10.1016/S0168-8510(97)00052-3
Judith K. Hellerstein, The importance of the physician in the generic versus trade-name prescription decision. The RAND Journal of Economics. ,vol. 29, pp. 108- 136 ,(1998) , 10.2307/2555818
Lesley Tilson, Kathleen Bennett, Michael Barry, The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland. European Journal of Health Economics. ,vol. 6, pp. 267- 273 ,(2005) , 10.1007/S10198-005-0302-5